Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PL-3301 oral gel in oropharyngeal candidiasis (Phase II, randomized, double-blind, placebo-controlled)
CTR20263156Phase 2Active
- Sponsor
- Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd.
- Start
- Aug 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of PL-3301 in oral candidiasis, sponsored by Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd.. Started Aug 2026; status: active.
02
Drugs
PL-3301
03
Conditions
oral candidiasis
Beyond the preview
Go deeper on CTR20263156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263156.